Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5154MR)

This product GTTS-WQ5154MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5154MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13840MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ15317MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ5076MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ10865MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ8182MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ14714MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ15338MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ5419MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW